Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, announces the completion of its merger with VYNE Therapeutics Inc. (“VYNE”), and the previously announced private financings totaling approximately $200 million. The combined company will operate as Yarrow Bioscience, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on Tuesday, July 28, 2026, under the ticker symbol “YARW.”
Read the full article: Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics //
Source: https://www.businesswire.com/news/home/20260727317637/en/Yarrow-Bioscience-Announces-Closing-of-Merger-with-VYNE-Therapeutics-and-Initiation-of-Dosing-in-Phase-2a2b-Trial-of-YB-101-a-Potential-First-in-Class-Treatment-for-Graves-Disease-and-Thyroid-Eye-Disease